An anti-idiotope monoclonal antibody (MAb), called CAl (Ab2), was produced in mice against MAb 2C7, which recognizes a widely in vivo-expressed gonococcallipooligosaccharide (LOS) epitope. Mice immunized with MAb CAl initially had a 2.S-fold increase in IgG (12-fold after a booster) but no increase in IgM anti-LOS (Abl') antibody. Control mice immunized with LOS had a 4.5-fold rise in IgG and 4-fold rise in IgM anti-LOS antibody. In rabbits, MAb CAl elicited a 9-fold rise in IgG and a 3.3-fold rise in IgM anti-LOS (Abl') antibody. Abl' antibody bactericidal activity was 1-2 logs greater than that produced by immunization with LOS. Abl' mediated complete human polymorphonuclear leukocyte phagocytosis of 2C7 epitope-positive (but not 2C7 epitopenegative) gonococci. MAb CAl acts as a molecular surrogate (Ab2P) for the nominal LOS antigen and may form the basis for vaccine candidates for human immunization against Neisseria gonorrhoeae.
The prevention of infection with Neisseria gonorrhoeae, particularly the severe complications of pelvic inflammatory disease, has been the goal of many investigators in ongoing efforts to develop an effective antigonococcal vaccine. The antibody response to natural gonococcal infection is predominantly directed against pili, opacity (Opa) proteins, and lipooligosaccharide (LOS), with lesser amounts directed against porin protein I (Por) [1] . Opa proteins, which are variably expressed in vivo, can provoke different immune responses in persons infected with the same strain [2] . Prior attempts at gonococcal vaccine development have focused on surface protein antigens that mediate mucosal attachment (e.g., pili) or elicit a bactericidal immune response (Por).
Clinical vaccine trials conducted with antigens purified from pili and Por have failed to produce a broadly protective immune response. An initial challenge study of a pilus-derived vaccine indicated type-specific protection against the strain used to prepare the vaccine but not against heterologous strains [3] . A large field trial of a single pilus-type vaccine given to men demonstrated rises in both homologous and heterologous antipilus antibody, but these responses were not associated with protection against gonococcal urethritis [4] . Similarly, a challenge study with a vaccine enriched with Por (reduction-modi-fiable protein [Rmp] and LOS were also present) did not demonstrate protection in men against the challenge strain that had also been used to prepare the vaccine [5] . An evaluation of the immune response to vaccine in that study and in a separate study [6] that used a pentavalent Por vaccine preparation (also containing small amounts of Rmp and LOS) indicated rises in antibody directed against both Rmp and LOS.
Antibody against LOS has several important functions: complement activation, bactericidal activity [7, 8] , and opsonic activity [9, 10] . Although these properties make LOS an excellent candidate vaccine antigen, considerable LOS heterogeneity is displayed by gonococci in vivo [II, 12] . Certain other limitations preclude the use of LOS as a vaccine antigen. First, the toxicity of the lipid A moiety of LOS limits its potential use as a vaccine immunogen. Second, purification of oligosaccharide (OS) from LOS may modify its antigenicity [13] and may result in a T cell-independent saccharide antigen that may be poorly immunogenic [14, IS] .
Alternative strategies to the use of pure saccharide vaccines include conjugation to a protein carrier and production of antiidiotope monoclonal antibodies (MAbs) that may act as functional "molecular mimics." Several investigators have reported anti-idiotopes that induce antigen-specific immune responses to the polysaccharide capsules of Escherichia coli Kl3 [16] , Neisseria meningitidis group C [17, 18] , and Streptococcus pneumoniae [19, 20] . Mice that were immunized with a synthetic peptide derived from the anti-idiotypic MAb that mimics group C meningococcal capsular polysaccharide were protected against challenge with a lethal dose ofN meningitidis group C [18] . A Pseudomonas aeruginosa lipopolysaccharide (LPS) anti-idiotope elicited an LPS-specific antibody response that was functionally active and protective in a murine model of fatal P. aeruginosa sepsis [21, 22] . An anti-idiotope directed against P. aeruginosa mucoid exopolysaccharide elicited spe-cific antibodies that opsonized P. aeruginosa for phagocytic killing [23] . Other investigators were able to block the bactericidal activity of a MAb directed against gonococcal LOS using polyclonal anti-idiotypic antibodies obtained from rabbits [24] . However, these studies were limited by lack of definition of the LOS epitopes and limited investigation of the degree of expression of the epitopes across multiple gonococcal strains. We describe the development and characterization of an antiidiotope MAb directed against a widely in vivo-expressed gonococcal LOS epitope identified by MAb 2C7.
Methods
Gonococcal strains and antigens. Transparent, nonpiliated gonococci were grown on solid media supplemented with 1% Isovitalex equivalent [25] for 12-14 h in candle extinction jars at 37°C [26] . LOSs were prepared from stably serum-resistant (SR) strains WG [27] and 71H [7] isolated from patients with disseminated gonococcal infection and from a serum-sensitive (SS) strain 24-1 [10] isolated from a patient with pelvic inflammatory disease, using a modification of the hot phenol-water method [28] .
Generation of anti-idiotope Ab2 antibodies. Eight-week-old pristane-primed BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were immunized by intraperitoneal (ip) injection of 10 5 hybridoma cells secreting MAb 2C7 [11] . MAb 2C7 (IgG3~) identifies an LOS epitope of gonococcal LOS that is stably expressed on 95% of gonococci in vivo and after multiple in vitro passages, is immunogenic in natural infection, is a bactericidal target in vitro, and is not obscured by sialylation [29] . Splenocytes were harvested and fused with the Sp2/0-Ag14 myeloma cell line, and stable hybridomas were selected in hypoxanthine-aminopterin-thymidine medium. Supernatants from the clones initially were screened for antibody (IgG or IgM) production by ELISA. Antibody-producing clones were then screened by immunodot assay [30, 31] for binding to biotinylated MAb 2C7. Purified MAb 2C7 was labeled with biotin (Pierce, Rockford, IL) at a ratio of 1.7 nmol of biotin! 1 nmol of IgG [32, 33] . Positive clones were then screened by competitive and displacement ELISAs (described below) to confirm their specificity for MAb 2C7. One clone (CAl), which produced large quantities of IgMK antibody, was further subcloned in soft agarose. Ab2 antibody was purified from clone CA I supernatants by affinity chromatography (goat anti-mouse IgM-conjugated agarose; Sigma, St. Louis) [10] .
Ab2 screening ELISAs. Competitive and displacement assays were done using 24-1 LOS (containing 2C7 epitope) affixed to microtiter wells. In the competitive ELISA, varying dilutions of Ab2 supernatant were mixed with a fixed amount of biotinylated MAb 2C7 before incubation with solid-phase LOS. The displacement ELISA was done by incubation of a fixed amount ofbiotinylated MAb 2C7 with LOS affixed to microtiter wells, followed by incubation with varying dilutions of Ab2 supernatant. In both assays, the remaining bound biotinylated MAb 2C7 was assessed using an avidin-alkaline phosphatase conjugate (Sigma).
Induction and measurement ofAbl' response in a murine (syngeneic) system. Abl' antibodies were induced in 12-week-old BALB/c mice (Jackson Laboratories). We used ip injection of different concentrations (1, 10, 100, or 200 J-lg) of MAb CA 1 (Ab2) diluted in PBS as described by others [21] to optimize the Ab I' antibody response to MAb CA 1. Controls included sera obtained from animals immunized with PBS, 10 J-lg of an irrelevant IgMK MAb (Sigma), or 10 J-lg of 24-1 LOS. Booster immunizations consisted of the same dose of the original antigen given ip 2 weeks after the primary injection. Sera were obtained by tail bleed at 0, 7, 14, 21, and 28 days after primary immunization. Quantitative determination of IgG and IgM antibody responses to 2C7 epitope was measured by ELISA using solid-phase 24-1 LOS (80 J-lg/mL coated to microtiter plate wells), incubation with varying dilutions of murine sera, and detection with alkaline phosphatase-conjugated goat anti-mouse IgG or IgM (Sigma) [34] . Standard curves for murine IgG and IgM determination were generated using methods substantially similar to those used to measure human IgG and IgM responses against LOS antigen [35] .
Induction and measurement ofAbl' response in a rabbit (xenogeneic) system. Six-week-old New Zealand White rabbits (Pine Acres Farm, Norton, MA) were immunized subcutaneously with different concentrations (5, 10,50, or 100 J-lg) ofMAb CAl (Ab2) coupled to keyhole limpet hemocyanin (KLH) [36] and emulsified with complete Freund's adjuvant (CFA) to optimize the Ab1' antibody response. For controls, we immunized with 100 J-lg of group C meningococcal capsular polysaccharide (Connaught Laboratories, Philadelphia) or 100 J-lg of24-1 LOS, each coupled to KLH [36] and emulsified with CFA. Booster doses were administered subcutaneously 2 weeks after primary immunization and consisted of the same dose of the original antigen, each coupled to KLH and emulsified with incomplete Freund's adjuvant (IFA). Sera were obtained at day 0 and weekly thereafter. Quantitative IgG and IgM anti-2C7 epitope antibody responses were measured as above except that the detector antibodies were alkaline phosphataseconjugated goat anti-rabbit IgG or IgM antibody (Sigma). Standard curves for rabbit IgG and IgM determination were generated using methods substantially similar to those used to measure human IgG and IgM responses against LOS antigen [35] . Specificity of the IgG and IgM Ab I' antibody responses was assessed by immunodot assay [30, 31] of pre-and postimmunization rabbit sera against solid-phase MAb CAl (Ab2) and control antigens. In addition, polyclonal rabbit anti-murine IgM (Accurate Chemical, Westbury, NY) was screened against the same antigens to assess possible cross-reactivity to LOS through an anti-isotype response. Immunodot blots were probed with either alkaline phosphatase-conjugated goat anti-rabbit IgG or IgM antibody (Sigma) and exposed to substrate [31] for 2 min.
Bactericidal activity of Abl' response. Routine bactericidal assays [25] were undertaken to assess the bactericidal activity of pre-and postimmunization sera (diluted I: 10, 1:100, and 1:1000) from mice and rabbits against SS strain 24-1, sialylated strain 24-1 (24-1 NANA [SR]), and SR strain WG. Gonococci were sialylated as described [29] . As a source of complement, normal mouse or rabbit serum (25 J-lL; Life Technologies GIBCO BRL, Gaithersburg, MD) was absorbed with glutaraldehyde-fixed gonococci [37] to remove antibody-mediated bactericidal activity before use in the assay.
Opsonophagocytic activity ofAbl' response. The gonococcal opsonization and phagocytosis assay developed to assess effects mediated by MAb 2C7 (Ab 1) [29] was used to characterize the response mediated by opsonization with rabbit preimmunization or 14-days-postimmunization (Abl') sera. Lucifer yellow-stained organisms were allowed to be phagocytosed by human polymorphonuclear leukocytes (PMNL) , followed by incubation with biotin-labeled MAb 2C3. MAb 2C3 binds to the gonococcal lipoprotein surface antigen H.8 [38] and binds only to gonococci adherent to but not phagocytosed by PMNL. The mixtures were finally incubated with streptavidin-phycoerythrin-Texas red (SAPETR; Life Technologies), washed , fixed with Haema-Iine 2 (SeronoBaker Diagnostic s, Allentown, PA) containing 1% paraformaldehyde, and stored on ice until analyzed. Flow cytometric analysis of the fixed PMNL-gonococcal reaction mixtures was done on a single argon-ion laser (Becton Dickinson FACS Systems, Sunnyvale, CAl .
Fluorescence emission in fluorescence I (FL I) and fluorescence 3 (FL3) channels was expressed as the mean fluorescent channel (the average intensity of fluorescence emitted by 10,000 cells). The intensity of fluorescence directly correlates with the mean fluorescence [39] . As phagocytosis proceeds, less MAb 2C3 and SAPETR is bound (yielding lower emission in FLJ), while the total number of Lucifer yellow -stained organisms present in the reaction mixture s (both adherent [external] and phagocytosed [internalized]) remains constant (i.e., constant emission in FLI). A decrease in the net fluorescence , calculated as the mean fluorescence in FL3 (red) minus the mean fluorescence in FLI (green), represents internalization of organisms by the PMNL. Aliquots of the reaction mixtures were also examined directly by fluorescence microscopy (Carl Zeiss, Thornwood, NY) as a visual control for internalization of organism s.
Results
Detection and characterization ofsyngeneic Ab2. Anti-idiotope antibody (Ab2) was produced by intraperitoneal immunization of pristane-treated BALB/c mice with hybridoma cells secreting MAb 2C7 (IgG3>'), followed by fusion ofsplenocytes with the nonsecreting Sp2/0-Ag14 myeloma cell line . After hypoxanthine-aminopterin-thymidine selection, supernatants were initially screened in an immunodot assay for the production of antibody that bound biotinylated MAb 2C7. Positive supernatants were subsequently characterized using a commercial immunoglobulin isotyping ELISA kit (Immunose1ect; Life Technologies); 101 of 144 supernatants produced IgMK antibody. We chose 21 wells that contained rapidly growing cells and tested binding in the supernatants to gonococcal LOS (strain 24-1, bearing the 2C7 epitope), coated on solid phase, in two additional ELISAs.
In the first ELISA (competitive), varying dilutions of Ab2 supernatant were tested for their ability to compete with biotinlabeled MAb 2C7 and to inhibit binding of MAb 2C7 to LOS fixed on solid phase. Ten of the 21 supernatants showed > 45% inhibition of MAb 2C7 binding to LOS in this assay at 1:8 dilutions of the supernatants. The remaining supernatants showed less (30%~45 %) inhibition . Two negative controls (media and supernatant from non-antibody-producing cells [diluted I:8]) showed < 15% inhibition.
We tested 5 ofthe 10 supernatants that gave >45% inhibition in the competitive ELISA in a second (displacement) ELISA. In the displacement ELISA, the ability of varying dilutions of Ab2 supernatant to displace biotin-labeled MAb 2C7 prebound to LOS on solid phase was assayed. Four of 5 supernatants (l :2 dilution) displaced > 60% of biotin-labeled MAb 2C7 and one displaced 40%. A negative control (supernatant from nonantibody-producing cells [1:2 dilution]) showed < 20% displacement. One of the 5 clones (named MAb CA I) that produced large quantities of IgMK antibody was further subcloned by the soft agarose method and purified by anti-mouse IgMagarose affinity chromatography. Biotinylated MAb 2C7 was then used as a probe to confirm binding to purified MAb CA 1 (Ab2) in an immunodot assay (figure I).
Indu ction and characterization ofsyngeneic Ab l' response. Twelve-week-old BALB lc mice were immunized as described in Methods. The optimal response to MAb CAl immunization was obtained with the lO-J-lg dose (figure 2). As measured by ELISA against solid-phase strain 24-1 LOS, miee developed a 2.5-fold rise in IgG anti-LOS antibody 14 days after primary immunization. Booster immunization with MAb CA I at 14 days elicited rapid IgG anti-LOS antibody production to a level l2-fold higher than the preimmunization level, suggestive of T cell-dependent Ab I' stimulation. Control mice immunized with an irrelevant IgMK MAb (Sigma) did not demonstrate a rise in anti-LOS IgG, indicating specificity of the anti-MAb CAl Ab l ' response. Mice immunized with LOS had a maximal rise (4.5-fold) in anti-LOS IgG (figure 2) after boosting that was accompanied by a 4-fold rise in anti-LOS IgM that peaked (718 J-lg/mL) 14 days after primary immunization and fell despite subsequent booster doses. No anti-LOS IgM response to MAb CAlor irrelevant IgMK MAb was seen. CAl (Ab2) bound to whole gonococci (strain 24-1), purified gonococcal (strain 24-1) LOS, and the anti-idiotope MAb CAl (Ab2). Ab1' -containing sera also bound to irrelevant murine IgM MAb (10 J-Lg; Sigma), indicating a concomitant anti-isotype response. Antibody from rabbits immunized with C-MCP (controls) bound only to whole group C meningococci. Antibody from rabbits immunized with murine IgM (Accurate Chemical) bound to murine IgM MAb (Sigma) and to MAb CAl equally but not to whole gonococci or purified LOS (strain 24-1) or whole group C meningococci, indicating an anti-isotype response only. In general, the IgM Ab l' response elicited was similar to, but of lesser magnitude than, the IgG response (figure 4). Although the irrelevant IgM MAb stimulated a brisk IgG response against both MAb CA 1 and irrelevant IgM MAb, no IgM response was measurable in this assay (figure 4). None of the preimmunization rabbit sera bound the antigen targets (data not shown). Thus, Ab l' elicited in rabbits by immunization with MAb CAl (Ab2) bound to the anti-idiotope Ab2 and displayed binding specificity that mirrors that of the primary antibody MAb 2C7 (Ab 1).
The ability of rabbit Ab l ' antibody elicited by MAb CA 1 to compete with Ab 1 (MAb 2C7) for binding to LOS from gonococcal strain 24-1 was assessed by inhibition ELISA. When LOS binding sites were saturated with MAb 2C7 (1: 100 dilution), 84% of anti-LOS IgG antibody and 68% of anti-LOS IgM antibody in Ab 1' -containing sera was inhibited, in a dosedependent manner, from binding to LOS. Antibody elicited by primary antigen (LOS) immunization competed only minimally «10%) with the binding of MAb 2C7 Abl to LOS. This indicated that the polyclonal antibodies were directed against multiple LOS epitopes and that antibody that could have bound to the 2C7 epitope may have been present in too Iowa concentration to have shown inhibition (data not shown). Control Rabbits antibodies present in preimmunization rabbit sera and post -C-MCP immuniz ation sera did not inhibit MAb 2C7 binding to LOS . These data suggested that immunization with MAb CA I (Ab2) elicited a specific Abl' antibody response directed against the LOS epitope defined by MAb 2C7 (Ab I) . Bactericidal activity of the syngeneic and xenogeneic Ab l' response. Separate experiments have established the ability of the primary antibody, MAb 2C7 (Ab l ), to kill both SS and SR gonococci that express the 2C7 LOS epitope [29] . The bactericidal activity of the Ab I' response to CA I and LOS in both mice and rabbits was characterized using minor modifications of established procedures for bactericidal assays [25] . Normal mouse and rabbit serum were absorbed with homologous glutaraldehyde-fixed gonococci (strain 24-1, WG , or 71H, respectively) before use as a complement source [37] in the respective assays using these organisms and immune serum. MAb CA I immunization induced I 10glO greater kilIing activity against the SS strain 24-1 in mice and 2 10gsIO greater killing activity in rabbits than LOS immunization (figure 5). Sialylation of strain 24-1 decre ased killing by Abl' sera by I log]() dilution; however, activity exceeded that of post -LOS immunization sera by I Iog., dilution . MAb CA 1 immunization also elicited a bactericidal Ab I' response against the SR strain WG in both species equivalent to that elicited by LOS immunization (figure 5). No killing (mice) or no excess killing (rabbits) of the SR strain 71H, which does not express the 2C7 LOS epitope, was observed in immune serum (data not shown) . Taken together, these data indicate that immunization with the antiidiotope (Ab2) MAb CAl evokes a specific, functional bactericidal response, in both syngeneic and xenogeneic systems, against the primary gonococcal LOS epitope. Moreover, this bactericidal response is directed against both SS and SR gonococci that express the 2C7 LOS epitope. Killing activity of Ab I' sera is decreased, but not abolished, by sialylation of SS gonococci.
Opsonophagocytic activity ofthe xenogeneic Ab I' response. Separate experiments have established the ability ofthe primary antibody, MAb 2C7 (Ab I) , to mediate opsonophagocytosis of both SS and SR gonococci that express the 2C7 LOS epitope [29] . Control experiments were done to establish baseline mean fluorescence of organisms after staining with Lucifer yellow and counterstaining the biotinylated MAb 2C3-SAPETR complex and to demonstrate that SAPETR counterstaining did not quench the green fluorescence due to Lucifer yellow. In add ition, the mean fluorescence in FLI (green) remained constant in the individual reaction tubes during the incubation period, thus permitting accurate quantitation of the number of organisms present in the reaction mix tures . Corroboration of the flow cytometric data was obtained by direct fluorescent microscopic examination of samples obtained concurrently from the PMNLorganism reaction tubes. At time zero, all organisms were exterior to the PMNL and yellow. After 30 min at 37°C, most of the organisms were inside the PMNL and green (indicating internalization). When opsonized with either preimmune or post-MAb CAl immunization (Ab I') rabbit serum, PMNL adherence (0 time points, figure 6 ) of SS gonococcal strain 24-1 was greater than that of SR gonococcal strains WG and 71H. Comparison of pre-and postimmune rabbit sera showed that opsonization with Ab l ' increased adherence of SS strain 24-1 gonococci by 14% ( figure 6A ) and of SR strain WG gonococci by 48% ( figure  6B ). There was no difference in adherence of SR strain 71H gonococci lacking the 2C7 LOS epitope ( figure 6C ) regardless of the opsonin used.
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When opsonized with pre immune rabbit serum, SS gonococci (strain 24-1) were only minimally (9%) ingested, and there was no ingestion of either SR gonococcal strain at 30 min (figure 6). When Ab l ' (post-MAb CAl [Ab2] immunization rabbit serum) was used as the opsonin, both SS strain 24-I gonococci (figure 6A) and SR strain WG gonococci (figure 6B) were completely ingested (i.e., the mean fluorescence in the FL3 channel returned to the level observed with Lucifer yellow-labeled organisms alone = net fluorescence of 0) by PMNL after 30 min at 37°C. Neither opsonin caused ingestion of SR gonococci lacking the 2C7 LOS epitope (strain 7IH), indicating specificity of the response ( figure 6C ).
These data suggest that Ab I' antibodies elicited by MAb CA I (Ab2) immunization in a xenogeneic system are specific for the 2C7 LOS epitope that leads to enhanced binding to human PMNL and internalization of gonococci expressing the 2C7 LOS epitope. In addition, the rate of ingestion of both SS and SR gonococci when Ab l ' was used as the opsonin ( figure 6 ) was comparable to that with MAb 2C7 (Abl) [29] . Collectively, these data indicate that the xenogeneic Ab l ' response to MAb CAl (Ab2) immunization is functionally specific for the 2C7 LOS epitope. Thus, MAb CAl (Ab2) represents an Ab2,B that mimics the nominal gonococcal LOS epitope.
Discussion
Natural infection with N. gonorrhoeae elicits immune responses against pili, Opa proteins, and Por, but the bactericidal response is directed primarily against LOS [40] . Differences in LOS epitopes have been found to relate to the degree of sensitivity of gonococcal isolates to killing by normal human serum [41, 42] ; such sensitivity in tum is also predictive of the degree oflocal genital inflammation that ensues [43] . Gonococcal LOS has also been shown to mediate damage to human fallopian tube tissue [44] . Although LOS provides an abundant and clinically relevant target for vaccine development, the immune response to LOS has not been thought to be protective [40] . The heterogeneity of gonococcal LOS [11, 12] and the well-described similarities of certain LOS epitopes to human red blood cell precursor antigens [45, 46] may represent significant difficulties in the use of LOS itself as vaccine antigen. However, previous vaccine trials of gonococcal protein antigens, such as pilus [4] and Por [5] , have not proven protective. In the case of one Por vaccine, small amounts ofRmp contaminating the antigen preparations led to the development of blocking antibody capable of subverting a potentially bactericidal response [5, 6] . Potential vaccines based on gonococcal antigens (pili and Opa proteins) that mediate epithelial cell attachment may be limited by extreme antigenic variability of these proteins [47, 48] .
Considerable LOS heterogeneity is also displayed by gonococci in vivo [11, 12, 49, 50] , but antibody against LOS has been demonstrated to have several important functions: complement activation, bactericidal activity [7, 8] , and opsonic activity [9, 10] . Unlike the heterogeneity generally seen with gonococcal LOS, MAb 2C7 [11] identifies a gonococcal LOS epitope that is expressed both in vitro and in vivo on 95% of randomly tested gonococci and is maintained after multiple in vitro passages. The 2C7 epitope is also immunogenic in the setting of natural infection (both disseminated infection and endometritis), is a target for bactericidal and opsonophagocytic antibody in vitro, and is not obscured by sialylation [29] . The local immune response in the genital tract during gonococcal infection mirrors that in serum and consists of IgG and IgA directed against LOS, Por, Opa, and pili [51, 52] . Therefore a local response against the 2C7 epitope may be functionally relevant. Immunization with a gonococcal outer membrane preparation that contained small amounts of LOS elicited a rise in serum antibody directed against the 2C7 epitope [53] . These data establish that the 2C7 epitope is immunogenic in the setting of vaccination with other gonococcal antigens.
Although the gonococcus may mimic human mucosal cellular surfaces and evade immune defense detection by way of antigenic similarities between some gonococcal LOS components and mammalian glycosphingolipids (GSL) [45, 46, 54, 55] , no cross-reactivity between MAb 2C7 and any of the previously known human GSL structures that cross-react with gonococcal LOS has been observed [29] . The 2C7 epitope thus may exhibit characteristics suitable for evaluation as a candidate vaccine antigen; however, certain limitations would preclude its use either as a component of intact LOS or as an isolated OS. First, the toxicity of the lipid A moiety of LOS [56] limits its potential use as a vaccine immunogen. Second, purification of OS from LOS may modify its antigenicity [13] and result in a T cell-independent saccharide antigen with poor immunogenicity [14, 15] .
The current studies describe the production of an anti-idiotope MAb (MAb CAl) by immunization of mice and rabbits with MAb 2C7. The immune response (Ab1') elicited in both syngeneic and xenogeneic systems was specific for gonococcal LOS. These Ab l' antibodies competed equally with Ab 1 (MAb 2C7) for binding to LOS, indicating that MAb CAl represents an Ab2,B molecular mimic of the nominal gonococcal LOS antigen. We found that the optimal immune response was obtained at lower doses of MAb CA 1, as has been observed with an anti-idiotope MAb that mimics N. meningitidis group C capsular polysaccharide [18] . This result may relate in part to the ability of MAb CA 1, as an IgM molecule, to present a multivalent antigen. Higher concentrations of such antigens are capable of cross-linking membrane IgM receptors on B cells and inducing B cell tolerance, or clonal anergy [57] . Some saccharides, such as N. meningitidis group A capsular polysaccharide, can elicit a T cell-dependent response [58] . However, most bacterial saccharide antigens, including the capsular polysaccharides of Haemophilus infiuenzae type b, S. pneumoniae, and N meningitidis group C, induce a T cell-independent response [14, 59, 60] and require protein conjugation to elicit a memory response. The pattern of IgG and IgM anti-LOS antibody resulting from MAb CA 1 immunization in the current studies was indicative of a T cell-dependent response.
The Ab l' response to MAb CAl immunization was bactericidal and specific for gonococci expressing the 2C7 LOS epitope, corroborating similar results obtained with polyclonal rabbit anti-idiotypic antibodies directed against LOS [24] . In the case of 1 of the strains used in this study for characterization (24-1, an SS strain), immunization with MAb CAl elicited 10-fold greater killing activity in mice and 100-fold greater killing activity in rabbits than did immunization with 24-1-derived LOS. Only certain epitopes contained in whole LOS elicit bactericidal antibodies [61, 62] ; thus, stimulation with the correct epitope may yield a disproportionately greater bactericidal response. Bactericidal activity against both SS and SR strains was induced, paralleling the activity of MAb 2C7 (Ab1) [29] . Sialylation did not prevent killing by Ab l' sera. The difference in bactericidal activity against SS and SR strains found in these studies (figure 5) may relate to differences in complement processing on the surface of these strains. This hypothesis is supported by the observation that, in an in vitro phagocytosis assay, these Ab l ' antibodies mediated complete ingestion of lID 1996; 174 (December) both SS and SR gonococci expressing the 2C7 LOS epitope in the absence of complement [29] . However, gonococcal strain 24-1 is effectively killed by anti-LOS IgM [7] while strain WG is not [27] ; thus, the differences in bactericidal activity could simply be due to the greater efficiency of IgM in activating complement. Because phagocytosis in these experiments was solely dependent on antibody, this suggests that 2C7 epitope expression is equivalent for SS and SR gonococci.
Ab l' -opsonized SS and SR gonococci expressing the 2C7 LOS epitope were phagocytosed equally well; therefore, sialylated organisms (also SR [63, 64] ) were not examined. Nevertheless, sialylation, because of its down-regulating effect on the alternative pathway of complement [65] , may also impart additional constraints on the ability of the human host to dispose of gonococci made SR by sialylation [66] by limiting the amount of C3b deposition on the surfaces of organisms. Collectively, these data indicate that immunization with the anti-idiotope MAb CAl elicits a specific bactericidal and opsonophagocytic response against gonococci.
Anti-idiotope vaccines directed against cancer antigens have been used with some success as therapeutic agents in several human clinical trials. Two goat polyclonal anti-idiotope antibodies directed against a 40-kDa colorectal cancer-associated glycoprotein elicited idiotope-specific humoral and T helper cell proliferative responses in patients with colorectal cancer [67] . Four of 30 patients with advanced (Dukes stage D) cancer experienced stabilization of tumor growth and 10 of 13 patients with Dukes stage B or C cancer were without detectable disease 2-5 years after the start of therapy [67] . A recent clinical trial of a murine anti-idiotope antibody vaccine effectively elicited specific Ab l' and T cell proliferative responses to carcinoembryonic antigen, an otherwise nonimmunogenic tumor glycoprotein antigen, in patients with advanced colorectal cancer [68] . Similarly, 3 of 4 patients with cutaneous T cell lymphoma treated with a murine anti-idiotope MAb mimicking a unique cell surface glycoprotein expressed exclusively by T cell leukemia and lymphoma cells developed a brisk humoral and cellular anti-idiotype-specific response; 1 patient evidenced a dramatic (>90%) regression of his tumor masses [69] . These results indicate that an anti-idiotope vaccine can effectively stimulate a specific active immune response in humans. MAb CAl may therefore be used for the derivation of a potentially protective vaccine candidate directed against gonococcal LOS that avoids the difficulties inherent in the use of LOS alone.
